Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Keytruda Marches On In Melanoma With NICE Nod

This article was originally published in Scrip

Executive Summary

Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) has been given the provisional green light from the British national health technology association NICE as a treatment for some patients with advanced melanoma which is either inoperable or metastatic – provided the US drug maker makes the immune-oncology therapy available at an agreed discounted price.

You may also be interested in...



AbbVie’s Skyrizi Tops Novartis’s Cosentyx In Psoriasis Contest

A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.

AZ Halts Epanova Study As High Placebo Effect Kills Acasti’s Omega-3 TRILOGY-1 Trial

Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.

MorphoSys Chooses Incyte As Its Global Tafasitamab Partner

MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel